10
views
0
recommends
+1 Recommend
1 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Glucocorticoid sensitivity in Behçet's disease

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Glucocorticoid (GC) sensitivity is highly variable among individuals and has been associated with susceptibility to develop (auto-)inflammatory disorders. The purpose of the study was to assess GC sensitivity in Behçet's disease (BD) by studying the distribution of four GC receptor (GR) gene polymorphisms and by measuring in vitro cellular GC sensitivity.

          Methods

          Healthy controls and patients with BD in three independent cohorts were genotyped for four functional GR gene polymorphisms. To gain insight into functional differences in in vitro GC sensitivity, 19 patients with BD were studied using two bioassays and a whole-cell dexamethasone-binding assay. Finally, mRNA expression levels of GR splice variants (GR-α and GR-β) were measured.

          Results

          Healthy controls and BD patients in the three separate cohorts had similar distributions of the four GR polymorphisms. The Bcll and 9β minor alleles frequency differed significantly between Caucasians and Mideast and Turkish individuals.

          At the functional level, a decreased in vitro cellular GC sensitivity was observed. GR number in peripheral blood mononuclear cells was higher in BD compared with controls. The ratio of GR-α/GR-β mRNA expression levels was significantly lower in BD.

          Conclusions

          Polymorphisms in the GR gene are not associated with susceptibility to BD. However, in vitro cellular GC sensitivity is decreased in BD, possibly mediated by a relative higher expression of the dominant negative GR-β splice variant. This decreased in vitro GC sensitivity might play an as yet unidentified role in the pathophysiology of BD.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: not found
          • Article: not found

          Behçet's disease.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Glucocorticoid resistance in inflammatory diseases.

            Glucocorticoid resistance or insensitivity is a major barrier to the treatment of several common inflammatory diseases-including chronic obstructive pulmonary disease and acute respiratory distress syndrome; it is also an issue for some patients with asthma, rheumatoid arthritis, and inflammatory bowel disease. Several molecular mechanisms of glucocorticoid resistance have now been identified, including activation of mitogen-activated protein (MAP) kinase pathways by certain cytokines, excessive activation of the transcription factor activator protein 1, reduced histone deacetylase-2 (HDAC2) expression, raised macrophage migration inhibitory factor, and increased P-glycoprotein-mediated drug efflux. Patients with glucocorticoid resistance can be treated with alternative broad-spectrum anti-inflammatory treatments, such as calcineurin inhibitors and other immunomodulators, or novel anti-inflammatory treatments, such as inhibitors of phosphodiesterase 4 or nuclear factor kappaB, although these drugs are all likely to have major side-effects. An alternative treatment strategy is to reverse glucocorticoid resistance by blocking its underlying mechanisms. Some examples of this approach are inhibition of p38 MAP kinase, use of vitamin D to restore interleukin-10 response, activation of HDAC2 expression by use of theophylline, antioxidants, or phosphoinositide-3-kinase-delta inhibitors, and inhibition of macrophage migration inhibitory factor and P-glycoprotein.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans.

              Alternative splicing of the human glucocorticoid receptor (hGR) pre-mRNA generates two highly homologous isoforms, termed hGR alpha and hGR beta. hGR alpha is a ligand-activated transcription factor which, in the hormone-bound state, modulates the expression of glucocorticoid-responsive genes by binding to specific glucocorticoid response element (GRE) DNA sequences. In contrast, hGR beta does not bind glucocorticoids and is transcriptionally inactive. We demonstrate here that hGR beta is able to inhibit the effects of hormone-activated hGR alpha on a glucocorticoid-responsive reporter gene in a concentration-dependent manner. [3H]-Dexamethasone binding studies indicate that hGR beta does not alter the affinity of hGR alpha for its hormonal ligand. The presence of hGR beta in nuclear extracts and its ability to bind to a radiolabeled GRE oligonucleotide suggest that its inhibitory effect may be due to competition for GRE target sites. Reverse transcription-PCR analysis shows expression of hGR beta mRNA in multiple human tissues. These results indicate that hGR beta may be a physiologically and pathophysiologically relevant endogenous inhibitor of glucocorticoid action, which may participate in defining the sensitivity of target tissues to glucocorticoids. They also underline the importance of distinguishing between the two receptor isoforms in all future studies of hGR function and the need to revisit old data.
                Bookmark

                Author and article information

                Journal
                Endocr Connect
                Endocr Connect
                EC
                Endocrine Connections
                BioScientifica (Bristol )
                2049-3614
                24 October 2012
                01 November 2012
                : 1
                : 2
                : 103-111
                Affiliations
                [1 ]Department of Internal Medicine, Erasmus MC University Medical Center 's-Gravendijkwal 2303015 CE, RotterdamThe Netherlands
                [2 ]Department of Immunology, Erasmus MC University Medical Center 's-Gravendijkwal 2303015 CE, RotterdamThe Netherlands
                [3 ]St John's Hospital JerusalemIsrael
                [4 ]Department of Medicine Hadassah-Hebrew University Medical Center JerusalemIsrael
                [5 ]Department of Ophthalmology King's College LondonUK
                [6 ]Academic Unit of Ophthalmology University of Birmingham BirminghamUK
                [7 ]Department of Oral Medicine Queen Mary's College LondonUK
                [8 ]University Hospital DamascusSyria
                [9 ]Department of Ophthalmology University of Cukurova School of Medicine AdanaTurkey
                [10 ]Department of Rheumatology, Erasmus MC University Medical Center RotterdamThe Netherlands
                Author notes
                Correspondence should be addressed to R A M Quax Email r.quax@ 123456erasmusmc.nl
                Article
                EC120056
                10.1530/EC-12-0056
                3681319
                23781311
                7bd44fda-5fb4-4f05-9db9-e56ff9d39b47
                © 2012 The Authors. Published by BioScientifica Ltd.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 10 September 2012
                : 20 September 2012
                Categories
                Research

                behçet's syndrome,single nucleotide polymorphism,glucocorticoid sensitivity

                Comments

                Comment on this article